Skip to main content

Table 1 Baseline characteristics of patients in the ELATE trial

From: Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

  Octreotide/everolimus (n = 22) Octreotide
(n = 23)
Age (yr) 52.9 (8.7) 50.7 (8.0)
Gender (m/f) 3/19 2/21
Diagnosis (PCLD/ADPKD) 9/13 6/17
Mutation in PCLD patients   
   PRKCSH 10 5
   SEC63 1 4
Body mass index (kg/m 2 ) 28.0 (3.5) 28.3 (3.9)
Systolic blood pressure (mmHg) 134 (14) 135 (15)
Diastolic blood pressure (mmHg) 87 (11) 84 (9)
Haemoglobin (mmol/L) 8.2 (0.7) 8.2 (0.7)
White blood count (*10 9 /L) 6.5 (1.6) 6.2 (1.4)
Thrombocyte count (*10 9 /L) 212 (56) 210 (62)
Creatinine (μmol/L) 72 (16) 68 (11)
Albumin (g/L) 40 (3) 40 (2)
Bilirubin (μmol/L) 14 (7) 14 (5)
γ-Glutamyl Transferase (U/L) 162 (131) 154 (122)
Glucose (mmol/L) 5.0 (0.5) 5.0 (0.8)
Cholesterol (mmol/L) 4.9 (0.9) 4.7 (1.0)
CA19-9 (E/mL) 123 (168) 134 (172)
  1. All continuous variables are stated as mean (SD)
  2. All PCLD patients underwent mutation analysis, no mutation analysis was performed on ADPKD patients
  3. There were no differences between the treatment arms